Therapeutics Solutions
4093 Oceanside Blvd. Suite B
Oceanside
California
92056
United States
Tel: 1-877-236-2332
25 articles about Therapeutics Solutions
-
Therapeutic Solutions International Division of Campbell Neurosciences Files Patent on QuadraMune™ for Treatment of Major Depressive Disorder
12/9/2020
Preclinical Data Suggests QuadraMune™ Prevents Stress-Induced Suppression of Neurogenesis More Effectively than Prozac
-
Therapeutic Solutions International Announces Positive QuadraMune™ Clinical Trial Data
12/1/2020
Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today new data from its clinical trial demonstrating an almost doubling of immune cell activity in healthy volunteers
-
Therapeutic Solutions International Reports Augmentation of Immunotherapy Efficacy in Breast Cancer Model Utilizing Patented NanoStilbene™ Nutraceutical Product
11/10/2020
Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today novel data supporting utilization of the Company's NanoStilbene™ product for enhancement of cancer immunotherapy clinical trials.
-
Therapeutic Solutions International Reports Positive Preclinical Data on Multiple Sclerosis using NanoStilbene™
10/19/2020
Company Continues on its Mantra of "Science Based" Nutraceutical Development in Expanding Uses of its Patented Nanotechnology based Pterostilbene
-
Therapeutic Solutions International Appoints Serena Robella as Director of Sales
10/12/2020
Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today the appointment of Serena Robella as Director of Sales.
-
Therapeutic Solutions International Announces Proof of Concept Data and Patent Filing for Neuroleukin™: The First Immune Based Suicide Prevention Biological Therapy
9/24/2020
Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today the launch of Neuroleukin™, a personalized biological product developed to prevent suicide
-
Therapeutic Solutions International Files Patent on Campbell Score™: The First Quantitative Tool for Assessment of Suicidal Propensity based on Immunological Markers
8/21/2020
Therapeutics Solutions International, Inc., (OTC Markets: TSOI), announced today filing a patent covering immunological means of quantifying risk of suicide. One embodiment of the patent is the Campbell Score™, a proprietary means of predicting risk of suicide based on ass
-
Therapeutic Solutions International Reports Reduction of Inflammation Associated Memory Impairment by QuadraMune™ Administration
8/5/2020
Animal Data has Potential Implications for Ongoing COVID-19 Prevention Study Company Continues Quest to Dominate Intellectual Property Regarding COVID-19 Associated Pathologies
-
Therapeutic Solutions International Reports Unexpected Findings of Synergy between QuadraMune™ and Diabetes Drug Metformin in Animal Models of COVID-19 Lung Damage
7/22/2020
New Data Suggests Nutraceutical Product May Amplify Known Beneficial Effects of AMPK Activation in Pulmonary Inflammation
-
Therapeutic Solutions International Reports QuadraMune™ Inhibits Inflammation Induced Blood Clotting: Possible Implication for Ongoing Covid-19 Prevention Clinical Trial?
7/13/2020
Therapeutics Solution International, Inc., (OTC Markets: TSOI), reported today new data showing that the ingredients of QuadraMune™ suppress expression of an inflammation stimulated molecule which is known to induce coagulation of blood. Inhibition of this coagulation-promoting molecule, called Tissue Factor, was synergistic with
-
Therapeutic Solutions International Universal Donor Immunotherapy StemVacs™ Activates Antiviral Immune Cells While Protecting Lungs From "Cytokine Storm"
6/30/2020
Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today new data and a patent filing showing its clinical-stage cancer immunotherapeutic product StemVacs™ appears to reduce innate immune induced inflammation in lungs while stimulating immune cells known to possess antiviral properties.
-
Therapeutic Solutions International Announces Intention to Use Clinical Stage NK Activating Cancer Immunotherapy for COVID-19
6/22/2020
Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today plans to utilize its clinical-stage cancer immunotherapy StemVacs™ for treatment of COVID-19 patients. Previously
-
Therapeutic Solutions International Reports Reduction of Brain Inflammation/Depression Associated Biochemical Pathway Using QuadraMune™ in Animal Studies
6/15/2020
Continued Basic Science Experiments Support New Patent Filing Covering Suppression of Indolamine 2,3 Deoxygenase Pathway by QuadraMune™
-
Therapeutic Solutions International Issues "NOT US" Notice to Shareholders
6/15/2020
Therapeutics Solutions International, Inc., issues the following cautionary notice to the shareholders and public at large.
-
Therapeutic Solutions International Reports QuadraMune Reduces Myeloid Suppressor Cells in 4T1 Mouse Model of Breast Cancer
6/11/2020
New Patent Filing Suggests Novel Mechanism of Immune Boosting Nutraceutical Can Augment Efficacy of Cancer Immunotherapy
-
Therapeutic Solutions International Initiates 500 Volunteer COVID-19 Prevention Clinical Trial Using QuadraMune™
6/8/2020
Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced the initiation of a clinical trial aimed at demonstrating safety and efficacy of its immune-boosting
-
Therapeutic Solutions International Announces Positive Preclinical and Clinical Evaluation of Nutritional Supplement QuadraMune™, Designed to Protect Against COVID-19
6/4/2020
Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today the submission to an international medical journal the results of pre-clinical and clinical evaluation of QuadraMune™ in 32 healthy
-
San Diego Top Doctor Collaborates with Therapeutic Solutions International to Report QuadraMune™ Immune Boosting Data in Clinical Trial
6/1/2020
Scientifically Formulated Nutraceutical Product Appears to Stimulate Natural Killer Cell Arm of Immune System Responsible for Suppression of Cancer and Viruses
-
Therapeutic Solutions International Leverages Filed and Issued Intellectual Property to Develop COVID-19 Nutraceutical Candidate: QuadraMune™
5/5/2020
Company Intends to Initiate Clinical Trials using Novel "Multipronged" Attack on Coronavirus Pathology
-
Therapeutic Solutions International Enters Into Multi-million Dollar Master Sales Agreement With WCTE, Inc.
12/23/2019
Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announces today the signing of another Master Sales Agreement with WCTE, Inc. to distribute our nutraceutical line of products.